Venous Thromboembolism Clinical Trial
Official title:
A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
Status | Completed |
Enrollment | 300 |
Est. completion date | April 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must have undergone reparative surgery within 72 hours after unilateral hip fracture, defined as fracture of the upper third of either femur - Must have started standard prophylactic treatment for VTE with low molecular weight heparin (LMWH) or heparin before surgery or within 24 hours after hip fracture surgery, and continued treatment with LMWH or heparin for at least five days, but not more than nine days, after surgery - Last dose of LMWH or heparin must have been administered at least 12 hours, but not more than 48 hours, before dosing with study drug - Females must have a negative serum pregnancy test - Must weigh at least 45 kg - Must demonstrate the mental and physical ability and willingness to follow all study-specific instructions - Must be able to read, comprehend and sign the Ethics Committee-approved informed consent form Exclusion Criteria: - Evidence of active bleeding - Clinical signs of VTE - Any medical requirement for (or intention to use) continued anticoagulation after randomization through the end of study - History of intracranial bleeding, hemorrhagic stroke, or gastrointestinal bleeding within 3 months of study start - Presence of active malignant disease - Hip fracture associated with multiple trauma, that places patient at excessive risk for hemorrhage or organ system failure, or that may make it difficult or impossible to perform bilateral lower limb venography - Intention to take aspirin at doses greater than 325 mg/day - Hemoglobin < 5.45 mmol/L (9 g/dL), hematocrit < 29%, or a platelet count < 100,000/mL at the screening visit - Elevated ALT or AST level > 3.0 times the ULN, or an elevated total bilirubin > 1.5 the ULN at the screening visit - Creatinine > 180 mmol/L (2.0 mg/dL) at the screening visit - Any other laboratory value at screening that the Investigator considers to be clinically significant and warrants exclusion from the study - Patient is currently breast feeding a child and wishes to continue breast feeding - Previous allergy to contrast material or any other contraindications to perform bilateral lower limb venography - The use of another investigational drug within 28 days of study entry |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Czech Republic | Nemocnice Ceske Budejovice, Urazove oddeleni | Ceske Budejovice | |
Czech Republic | FN s Poliklinikou Ostrava, Traumatologicke Centrum | Ostrava-Poruba | |
Czech Republic | FN Motol, Ortopedicka Klinicka UK 2.LF a FN Notol | Praha 5 | |
Czech Republic | FN Na Bulovce, Ortopedicka Klinika IPVZ a 1.LF UK ORT, Budinova 2 | Praha 8 | |
Czech Republic | VFN, I. Chirurgicka klinika | Praha-2 | |
Denmark | AAlborg Hospital | Aalborg | |
Denmark | Ortopaedkirurgisk Klinik, Farso | Farso | |
Denmark | Amtsygehuset i Gentofte | Hellerup | |
Denmark | KAS Herlev | Herlev | |
Denmark | Horsholm Hospital | Horsholm | |
Denmark | H:S Bispebjerg Hospital | Kobenhavn | |
Denmark | Silkeborg Hospital | Silkeborg | |
Norway | Orthopedics, Alesund Sykehus | Alesund | |
Norway | Skyehuset Innlandet HF | Gjovik | |
Norway | Skyehuset Innlandet HF | Lillehammer | |
Norway | Halfdan Wilhelmsens Alle 17 | Tonsberg | |
Sweden | Ortoped Kliniken, Sahlgrenska Universitetssjukhus, Ostra | Goteborg | |
Sweden | Ortopedsektionen, Kirurgkliniken, Kungalvs Sjukhus | Kungalv | |
Sweden | Ortoped kliniken, Sahlgrenska Universitetssjukhus | Molndal | |
Sweden | Ortoped kliniken, NU-sjukvarden, Udevalla Sjukhus | Udevalla | |
Sweden | Ortoped kliniken, Sjukhuset i Varberg | Varberg |
Lead Sponsor | Collaborator |
---|---|
vTv Therapeutics |
Czech Republic, Denmark, Norway, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery. | |||
Primary | Evaluation of safety of once daily oral administration of TTP889 for three weeks | |||
Secondary | To assess the correlation between peak and trough plasma concentrations of TTP889 and clinical safety and efficacy outcomes. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 | |
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 |